| pubmed-article:21247529 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0128897 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0253486 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0006560 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0033413 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C1413188 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0752046 | lld:lifeskim |
| pubmed-article:21247529 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:21247529 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21247529 | pubmed:dateCreated | 2011-3-7 | lld:pubmed |
| pubmed-article:21247529 | pubmed:abstractText | CC chemokine receptor 2 (CCR2), expressed on the surface of circulating monocytes, and its ligand monocyte chemoattractant protein-1 (MCP-1; also known as CC-chemokine ligand 2) are present in atherosclerotic plaques and may have important roles in endothelial monocyte recruitment and activation. MLN1202 is a highly specific humanized monoclonal antibody that interacts with CCR2 and inhibits MCP-1 binding. The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (?2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L). Additionally, patients were genotyped for the 2518 A?G polymorphism in the promoter of the MCP-1 gene to investigate the correlation between this polymorphism and reduced C-reactive protein levels with MLN1202 treatment. Patients who received MLN1202 exhibited significant decreases in high-sensitivity C-reactive protein levels, beginning at 4 weeks and continuing through 12 weeks after dosing. Patients with A/G or G/G genotypes in the MCP-1 promoter had significantly greater reductions in high-sensitivity C-reactive protein levels than patients with the wild-type A/A genotype. In conclusion, MLN1202 treatment was well tolerated in this patient population and resulted in significant reductions in high-sensitivity C-reactive protein levels. | lld:pubmed |
| pubmed-article:21247529 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21247529 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21247529 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21247529 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:21247529 | pubmed:issn | 1879-1913 | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:DavidsonMicha... | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:XuJingJ | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:HuMingxiuM | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:Lekstrom-Hime... | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:LeeYihY | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:WyantTimT | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:GilbertJimJ | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:DonaldsonDebr... | lld:pubmed |
| pubmed-article:21247529 | pubmed:author | pubmed-author:MLN1202... | lld:pubmed |
| pubmed-article:21247529 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21247529 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21247529 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:21247529 | pubmed:volume | 107 | lld:pubmed |
| pubmed-article:21247529 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21247529 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21247529 | pubmed:pagination | 906-11 | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:meshHeading | pubmed-meshheading:21247529... | lld:pubmed |
| pubmed-article:21247529 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21247529 | pubmed:articleTitle | Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. | lld:pubmed |
| pubmed-article:21247529 | pubmed:affiliation | Archemix Corporation, Cambridge, MA, USA. jgilbert@archemix.com | lld:pubmed |
| pubmed-article:21247529 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21247529 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21247529 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21247529 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21247529 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| entrez-gene:6347 | entrezgene:pubmed | pubmed-article:21247529 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21247529 | lld:entrezgene |
